Effect of Statin Use on Mortality in Individuals With Cardiovascular-Kidney-Metabolic Syndrome: A Retrospective Propensity Score-Matched Cohort Study - PubMed
4 hours ago
- #statin therapy
- #cardiovascular-kidney-metabolic syndrome
- #mortality reduction
- Statin use in individuals with cardiovascular-kidney-metabolic syndrome (CKMS) is associated with a 27% reduction in all-cause mortality and a 26% decrease in cardiovascular mortality.
- The study utilized propensity score matching on NHANES data (1999-2018) with 4,762 matched CKMS patients, showing mortality benefits regardless of CKMS stage, though more evident in advanced stages.
- Atorvastatin and simvastatin reduced risks of both all-cause and cardiovascular mortality, while rosuvastatin only reduced all-cause mortality, with benefits more pronounced in intermediate total cholesterol (200-240 mg/dL) and LDL levels (130-160 mg/dL).
- The findings, based on a retrospective cohort design, suggest statin therapy's protective effects in CKMS, warranting confirmation through prospective studies with larger samples.